Cartesian's mRNA-based cell therapy offers a novel, outpatient approach for autoimmune diseases. Promising results, but Phase ...

Market Trends, Business Strategies, Competitive Intelligence, Clinical Trials, and Patent Trends Driving Growth from 2024 to 2029"Boston, July 10, 2025 (GLOBE NEWSWIRE) -- According to the latest ...

In recent years, the FDA has approved three complement inhibitors for gMG -- eculizumab (Soliris), ravulizumab (Ultomiris), ...

I’ve endured numerous rounds of radiation and taken thousands of pills—but CAR-T is the most effective therapy I’ve completed yet.

Several ASX-listed biotechs are advancing cell therapies to capture a share of a global market projected to reach US$48 ...

Despite promising science, Precigen has long-faced severe financial challenges and a very short cash runway into 2026. Click ...

Previously, due to the risk of cytokine release syndrome and neurological toxicities, many CAR T-cell therapies included a REMS requirement.

A new trial just getting underway at Scripps Research Institute in La Jolla is using two novel medications in combination to ...

Legend Biotech Corp. ADR advanced stock charts by Barron's. View LEGN historical stock data and compare to other stocks, and exchanges.

While data is promising, many questions remain about topics such as timing and doses in the treatment of hematologic malignancies.

Aussie researchers have used CRISPR gene editing tools to “armor” chimeric antigen receptor (CAR) T cells to activate additional cancer-fighting proteins at the tumor site, enabling them to target ...

Thermo Fisher Scientific Inc. (NYSE:TMO) ranks among the best CRISPR stocks to buy. On June 24, Thermo Fisher Scientific Inc.